Understanding Central Post-Stroke Pain

What Is Central Post-Stroke Pain?

Central post-stroke pain (CPSP) is a chronic neuropathic pain syndrome that develops after a stroke damages the central somatosensory system — the network of pathways in the brain responsible for processing pain, temperature and other sensory signals. Although CPSP is classically associated with thalamic stroke, it can occur after lesions anywhere along the spinothalamic and thalamocortical pathways, including the lateral medulla, thalamus, parietoinsular cortex and their connecting white matter tracts.

The condition was first described in 1906 by Joseph Jules Dejerine and Gustave Roussy, who recognised severe burning pain occurring after thalamic stroke. This classical presentation became known as Dejerine–Roussy syndrome or thalamic pain syndrome. Modern neuroimaging and lesion network mapping have shown that similar symptoms can arise from a broader range of stroke locations, provided the pain and temperature pathways are affected.

CPSP is one of the most treatment-resistant neuropathic pain conditions. Standard painkillers such as paracetamol and anti-inflammatory medications are often ineffective. Symptoms may persist for years and can profoundly affect sleep, mood, rehabilitation, independence and quality of life. In severe cases, the condition has been associated with major psychological distress and suicidal ideation.

How Common Is Central Post-Stroke Pain?

Across all stroke survivors, the pooled prevalence of CPSP is approximately 11%. However, the risk varies widely depending on the location of the stroke and whether the spinothalamic pathway is involved. Lesions affecting the thalamus, lateral medulla and thalamocortical white matter carry the highest risk.

Patients are at greater risk when the stroke involves the pain and temperature pathways, particularly the spinothalamic tract and its projections to the thalamus and insular cortex. Additional associations include greater stroke severity, reduced functional independence, post-stroke spasticity, depression and anxiety.

When Does CPSP Begin?

The onset of CPSP is highly variable. Some patients notice pain immediately after the stroke, whereas others develop symptoms gradually over weeks or months. This delayed presentation is a common reason why the diagnosis is missed.

Once established, CPSP is often persistent and may become a lifelong condition. Even when pain intensity appears moderate on a 0–10 scale, the effect on daily function and wellbeing can be profound.

Clinical Features of Central Post-Stroke Pain

CPSP presents with a characteristic combination of spontaneous and evoked neuropathic pain in a body region corresponding to the stroke lesion. The coexistence of numbness and hypersensitivity in the same area is one of the most important clinical clues.

Pain Quality and Character

Pain may be continuous, intermittent or both. Continuous pain is commonly described as burning, aching, freezing, pricking, squeezing or painful cold. Intermittent pain may be shooting, stabbing, lacerating or electric shock-like. Spontaneous dysaesthesia occurs in up to 85% of patients and may be experienced as painful tingling, prickling or numbness.

Pain Distribution

Pain is usually felt on the side of the body opposite the brain lesion and corresponds to the area of sensory disturbance. The affected region may be small and focal, such as the hand, or extensive, involving the entire arm, leg, trunk, face or a complete hemibody. The upper limb is the most commonly affected area overall.

Negative Sensory Signs (Sensory Loss)

More than 90% of patients demonstrate impaired pinprick and temperature sensation, reflecting damage to the spinothalamic tract. Cold sensation is particularly commonly affected. Light touch and vibration may be relatively preserved, which can appear paradoxical to patients who feel both numb and painfully sensitive at the same time.

Positive Sensory Signs (Hypersensitivity)

Patients often experience allodynia (pain from light touch), hyperalgesia (exaggerated pain from painful stimuli), dysaesthesia, aftersensations and temporal summation (wind-up). Cold allodynia is particularly characteristic. For some patients, even clothing, a light breeze or cold weather can trigger intense discomfort.

Aggravating and Relieving Factors

Symptoms commonly worsen with cold exposure, stress, emotional upset, light touch and movement. Rest, warmth, distraction and effective neuropathic pain treatment may provide partial relief.

Functional Impact

CPSP can severely disrupt sleep, concentration, mood and rehabilitation. Patients may struggle to tolerate physiotherapy, wear clothing comfortably, or use the affected limb. Depression and anxiety are common, and severe uncontrolled pain can lead to profound distress.

Why Central Post-Stroke Pain Develops and How It Is Diagnosed

Central post-stroke pain is best understood as a disorder of the central pain-processing network. It is not simply “pain from the stroke area”. It develops when a stroke damages the central somatosensory pathways, especially the spinothalamic tract and its thalamocortical connections, leading to loss of normal inhibitory control, excessive pain facilitation, central sensitisation and abnormal interpretation of sensory input.

Why Does Central Post-Stroke Pain Happen?

Under normal circumstances, pain is regulated by a balance between ascending nociceptive input, which carries pain and temperature signals upwards, and inhibitory control systems, which dampen excessive pain signalling. In central post-stroke pain, this balance is disturbed. A stroke may damage the lateral spinothalamic pathway and reduce normal inhibitory influence over medial thalamic and limbic pain networks. The result is thalamocortical disinhibition: pain-promoting circuits become relatively overactive because the normal restraining systems have been weakened.

1. Spinothalamic Tract Damage

The spinothalamic tract is the main pathway carrying pain and temperature information from the body to the brain. Damage anywhere along this pathway — from the lateral medulla through the thalamus to the insula, operculum and parietal cortex — is the core anatomical requirement for CPSP. This explains why patients often have impaired pinprick and cold sensation in the same area where they experience burning, painful cold, allodynia or dysaesthesia.

2. Thalamocortical Disinhibition

In normal physiology, lateral spinothalamic input helps regulate and restrain medial thalamic pain networks. When this lateral input is lost, the medial thalamus and related limbic pain pathways become disinhibited. This means that the normal “braking system” is weakened, allowing pain-promoting circuits to become overactive. This is one reason why patients may experience spontaneous burning or painful cold even when there is no new tissue injury.

3. Central Sensitisation and Neuroinflammation

After a stroke, injured central neurons can become hyperexcitable. Deafferented thalamic and cortical neurons may generate abnormal spontaneous discharges, while neuroinflammatory mediators such as TNF-α, IL-1β and IL-6 may further amplify pain signalling. The nervous system becomes sensitised, meaning that ordinary sensory input can be amplified into pain, and painful input may feel more intense or last longer than expected.

4. White Matter Disconnection

CPSP is increasingly understood as a network disorder rather than a problem caused by one small focal lesion. Interruption of thalamocortical and thalamoinsular white matter connections can carry a very high risk of CPSP. These connections link the thalamus with cortical regions involved in sensory discrimination, emotional salience, attention and motor responses to pain. This helps explain why CPSP can affect not only sensation, but also mood, sleep, rehabilitation and functional recovery.

5. Peripheral Afferent Contributions

Although CPSP is classified as a central neuropathic pain condition, your article highlights an important modern concept: ongoing peripheral sensory input may still contribute to pain. In sensitised central pathways, ordinary input from peripheral nerves may be misinterpreted as pain. This helps explain why selected patients may respond to peripheral nerve blocks, topical treatments or regional procedures, even though the original injury is central.

Who Is Most at Risk?

The strongest and most consistent risk factors are anatomical. CPSP is most likely when the stroke damages the spinothalamic tract, thalamus, lateral medulla, parietoinsular cortex or thalamocortical white matter pathways. Patient-level factors may contribute, but lesion location and sensory pathway involvement are the most important predictors.

A haemorrhagic stroke may appear to carry a high risk when it involves the thalamus, particularly the ventral posterior nuclei, but this is because of the anatomical location rather than haemorrhage itself. Similarly, ischaemic strokes involving the lateral medulla, thalamus, insula or thalamocortical pathways may carry a high risk.

Can CPSP Be Predicted Early?

There is currently no fully validated screening tool or imaging biomarker that can reliably predict CPSP in routine clinical practice before pain develops. However, several approaches are promising, especially structured bedside sensory examination, quantitative sensory testing and advanced neuroimaging.

Bedside Sensory Testing

The most clinically useful early predictor is the combination of reduced or absent pinprick and cold sensation with early positive sensory symptoms such as allodynia, hyperalgesia or dysaesthesia. Your article notes that early evoked pain or dysaesthesia within the first days after stroke increases the odds of CPSP at six months, and that the risk is even higher when combined with impaired pinprick and cold sensation.

Quantitative Sensory Testing and Machine Learning

Quantitative sensory testing can detect subtle abnormalities in cold detection, mechanical thresholds and pain thresholds that may not be obvious on routine examination. Your article describes emerging evidence that QST patterns obtained early after stroke, when analysed using machine-learning models, may predict future CPSP with promising accuracy. At present, this remains mainly a research tool rather than standard clinical practice.

Neuroimaging Biomarkers

Detailed lesion mapping may identify patients at high risk, particularly those with thalamic lesions involving the ventral posterior region, thalamoinsular white matter disruption, or lesions connected to pain-processing networks involving the thalamus, insula, cingulate cortex and inferior parietal regions. These approaches are scientifically important but are not yet routine clinical screening tools.

Neuropathic Pain Questionnaires

Questionnaires such as DN4, LANSS and PainDETECT may help identify neuropathic pain features in stroke survivors. They are useful as screening aids, but they do not replace careful clinical assessment and have not been fully validated as predictive tools specifically for CPSP.

How Is CPSP Diagnosed?

CPSP remains a clinical diagnosis of exclusion. This means that the symptoms, examination findings and stroke anatomy must fit, while other causes of pain are excluded or considered unlikely. The Klit diagnostic criteria provide a widely accepted framework and are especially useful for distinguishing CPSP from musculoskeletal pain, spasticity-related pain, shoulder pain, complex regional pain syndrome and peripheral neuropathic pain.

Supportive Diagnostic Features

Supportive features include burning pain, painful cold, electric shock-like pain, aching, pressing, stinging, pins-and-needles, dysaesthesia, cold allodynia and touch allodynia. A lack of primary relationship to local inflammation, movement injury or tissue damage also supports CPSP, although these conditions may coexist.

Differential Diagnosis

Other post-stroke pain syndromes must be considered carefully. These include hemiplegic shoulder pain, painful spasticity, musculoskeletal pain, complex regional pain syndrome, peripheral neuropathy, radiculopathy and persistent headache. More than one pain mechanism may be present in the same patient, which is why a detailed pain assessment is essential.

Medical Management of Central Post-Stroke Pain

Central post-stroke pain is one of the most difficult neuropathic pain conditions to treat. No single medication reliably produces complete or sustained relief. Treatment therefore needs to be multimodal, mechanism-based and realistic, with careful attention to pain relief, sleep, mood, rehabilitation, function and medication tolerability.

General Principles of Management

The aim of treatment is not simply to reduce a pain score, but to improve quality of life, sleep, rehabilitation participation, emotional wellbeing and independence. Patients should be told early that CPSP is usually a long-term condition and that treatment often requires a stepwise approach rather than one curative intervention.

Phase-Based Treatment Strategy

First-Line Medications

First-line medication choice should be individualised. Important factors include age, frailty, falls risk, cognition, cardiac conduction risk, renal function, sleep disturbance, anxiety, depression, spasticity and the pattern of pain. The strongest CPSP-specific options include duloxetine, lamotrigine, amitriptyline and gabapentinoids, although the evidence differs between drugs.

Other Oral Medications and Combination Therapy

Other oral medications may be considered when first-line drugs are ineffective, poorly tolerated or only partially effective. In practice, many patients require either a switch to a different mechanism or cautious combination therapy using lower doses of two complementary agents.

Infusion, Anti-Inflammatory and Specialist Pharmacological Options

Infusion therapies and short-course anti-inflammatory or bone-modulating treatments should be presented carefully. They may have a role in selected refractory or early cases, but the evidence is limited, often short-term, and not strong enough to support routine repeated use for all patients with CPSP.

Intravenous Lidocaine

IV lidocaine has been studied in central pain, including CPSP, and may reduce spontaneous pain, brush-induced allodynia and mechanical hyperalgesia during or shortly after infusion. However, the effect is usually transient. Your article correctly positions IV lidocaine mainly as a diagnostic or short-term pharmacological challenge, rather than a stand-alone long-term treatment.

Prednisone and Pamidronate

Your article notes that prednisone and pamidronate appeared promising in network meta-analysis, with large reported effect sizes. However, this evidence is based on small studies and should be interpreted cautiously. These treatments should not be presented as established routine long-term therapies for CPSP.

Emerging and Topical Therapies

Several emerging and topical treatments are of interest in CPSP, but most should be described as investigational, off-label or adjunctive. The strongest practical role is usually in selected patients with localised allodynia or a suspected peripheral afferent contribution to central sensitisation.

Emerging Pharmacological Therapies

Topical Treatments

Topical treatments may seem counterintuitive in a central pain condition, but they are relevant because your article highlights that CPSP may remain partly afferent-dependent. In sensitised central circuits, ongoing peripheral input may help maintain pain. Reducing peripheral input may therefore help some patients, especially when pain is localised and allodynia is prominent.

Practical Use of Topicals

• Lidocaine 5% patch: usually applied to the painful area for 12 hours on and 12 hours off, up to three patches depending on local guidance and clinical suitability.
• Capsaicin 8% patch: applied in specialist settings after appropriate preparation and monitoring; benefit, when present, may take time to emerge.
• Best response pattern: focal pain, localised allodynia, positive sensory symptoms and a clear superficial painful territory.
• Less suitable pattern: widespread hemibody pain dominated by numbness or deep central pain without a localised peripheral input component.

Rehabilitation, Psychological Therapy and Sleep Optimisation

Central post-stroke pain is not treated by medication alone. Because CPSP affects sensory processing, sleep, mood, rehabilitation engagement and day-to-day function, non-pharmacological treatment is an essential part of management. These approaches do not imply that the pain is psychological. They are used because persistent neuropathic pain changes how the nervous system processes sensation, movement, threat, attention and recovery.

The most effective approach is usually integrated care: medication optimisation alongside rehabilitation, sensory retraining, psychological pain strategies, sleep treatment and management of depression or anxiety where present.

Rehabilitation and Physical Therapy

Rehabilitation after stroke can be difficult when pain, allodynia or painful cold sensitivity limits movement and touch. The aim is not to force through severe pain, but to restore confidence, maintain function and gradually reduce the nervous system’s over-responsiveness.

Psychological Approaches

Psychological therapy is not used because CPSP is “imaginary” or “stress-related”. It is used because persistent pain affects attention, threat perception, sleep, mood, confidence, coping and rehabilitation engagement. These factors can amplify pain intensity and disability even when the original driver is neurological.

Sleep and Mood Optimisation

Sleep disturbance, depression and anxiety are common in patients with CPSP and can worsen pain sensitivity. Poor sleep lowers pain thresholds, increases fatigue, reduces rehabilitation engagement and makes medication side effects harder to tolerate. Treating sleep and mood is therefore a core part of pain management rather than an optional extra.

Practical Daily Strategies

• Pace activity: use planned activity and rest rather than repeated boom-and-bust cycles.
• Track triggers: identify cold exposure, stress, poor sleep, overactivity or touch-related triggers.
• Plan for flares: agree what to do during a flare, including medication timing, warmth, rest, relaxation and when to seek advice.
• Maintain rehabilitation: adapt therapy rather than stopping completely when pain increases.
• Address mood early: depression and anxiety should be treated actively because they worsen disability and pain tolerance.

Neuromodulation for Central Post-Stroke Pain

Neuromodulation is an important option for refractory central post-stroke pain because CPSP is a disorder of abnormal thalamocortical and wider pain-network processing. Rather than simply blocking pain at a peripheral site, neuromodulation attempts to alter the activity of dysfunctional central pain circuits.

Your article highlights that neuromodulation has a larger pooled effect size than pharmacotherapy in CPSP overall, with the 2025 meta-analysis reporting a moderate effect for neuromodulation compared with a smaller effect for medication. However, the evidence quality varies between techniques, and invasive neuromodulation should be reserved for carefully selected refractory patients after specialist multidisciplinary assessment.

Repetitive Transcranial Magnetic Stimulation (rTMS)

Repetitive transcranial magnetic stimulation is the best-established non-invasive neuromodulation technique for CPSP. It uses repeated magnetic pulses applied over the scalp to influence activity in the primary motor cortex and connected thalamocortical pain networks. It is particularly relevant in CPSP because motor cortex stimulation may restore top-down inhibitory control over hyperexcitable thalamic pain circuits.

Two recent meta-analyses in your article report large effects for rTMS over sham in CPSP, with standardised mean differences of approximately −1.45 and −1.15. The Quesada trial used 20 Hz neuronavigated M1 stimulation in four sessions spaced three weeks apart and reported 33.8% pain relief versus 13.0% with sham, with a 47% responder rate.

The long-term effect is less certain. Your article notes that rTMS may no longer be statistically superior beyond six months without maintenance, so patients should be counselled that rTMS is often a treatment programme rather than a one-off intervention.

Motor Cortex Stimulation (MCS)

Motor cortex stimulation is an invasive neurosurgical technique in which an epidural electrode is placed over the primary motor cortex and connected to a subcutaneous pulse generator. It is generally considered when CPSP is severe, persistent and refractory, particularly when the patient has shown a favourable response to rTMS but requires more sustained benefit.

Your article notes that the Kannan et al. 2025 meta-analysis reported a 53.1% mean VAS improvement and a pooled responder rate of 64% with MCS. AHA/ASA case series report more than 50% pain reduction in 50–83% of patients, with benefit sustained up to two years in some series. Long-term results may be better in thalamic CPSP than extrathalamic CPSP, which is mechanistically logical because MCS may act through top-down inhibition of hyperexcitable thalamic neurons.

Deep Brain Stimulation (DBS)

Deep brain stimulation is an invasive neurosurgical treatment that targets deeper pain-processing structures. Targets discussed in your article include the sensory thalamus, periventricular grey matter, posterior limb of the internal capsule, central lateral thalamus and emerging posterior-superior insular targets.

The Kannan et al. 2025 meta-analysis reported a 48.6% mean VAS improvement and a 62% responder rate for DBS. However, your article correctly emphasises that evidence is conflicting. The Nowacki et al. 2025 international multicentre study, the largest CPSP DBS series to date, reported a 36% responder rate at 12 months and identified the posterior limb of the internal capsule and sensorimotor thalamus as potential stimulation “sweet spots”.

Spinal Cord Stimulation (SCS)

Spinal cord stimulation has re-emerged as a potentially useful option in selected CPSP patients, despite the pain being central in origin. The rationale is that modulating spinal input may reduce the peripheral afferent drive that is misinterpreted by sensitised central pain networks.

Your article highlights the Hosomi et al. 2022 multicentre retrospective study from six Japanese centres, the largest CPSP neuromodulation study reported in your draft. In 166 patients with a mean baseline pain score of 8.2/10, trial stimulation produced a mean 42% pain reduction; 64% achieved at least 30% reduction; 59% reported being “much” or “very much” improved; and 106 patients proceeded to permanent implantation. At median 24-month follow-up, mean pain reduction remained 41.4%, with 59% maintaining at least 30% reduction.

Burst SCS and high-frequency 10 kHz SCS are theoretically attractive because they may avoid uncomfortable paraesthesia in allodynic patients. However, your article correctly notes that novel waveforms do not fully overcome the challenge of treating supraspinal central pain at the spinal level, and evidence remains limited.

Dorsal Root Ganglion Stimulation (DRG-S)

Dorsal root ganglion stimulation is mechanistically attractive because it can selectively modulate primary afferent neuron cell bodies before sensory input reaches the central nervous system. This fits with the emerging view that some CPSP may remain partly afferent-dependent, despite being classified as central neuropathic pain.

Advantages over conventional SCS include dermatomal specificity, posture-independent stimulation, lower energy requirements and access to different fibre types. However, your article is clear that CPSP-specific evidence is extremely limited, with only a single published CPSP case described. Wider DRG-S evidence is encouraging in CRPS and causalgia, but this cannot be directly extrapolated to CPSP.

Comparative Summary of Neuromodulation Options

Interventional Pain Procedures for Central Post-Stroke Pain

Although central post-stroke pain is classified as a central neuropathic pain condition, selected interventional pain procedures may still have a role. Your article highlights an important modern concept: CPSP may not always be generated autonomously within the damaged brain. In some patients, ongoing peripheral sensory input may be misinterpreted by sensitised central neurons and may help maintain pain.

This is known as the peripheral input hypothesis. It explains why some patients with CPSP may respond to ultrasound-guided peripheral nerve blocks, sympathetic blocks, regional procedures, pulsed radiofrequency or targeted botulinum toxin injections, particularly when there is localised allodynia, preserved but altered sensation, or a clear peripheral afferent component.

Peripheral Nerve Blocks

The strongest CPSP-specific evidence for interventional procedures comes from peripheral nerve blocks. The Haroutounian et al. pilot study tested whether blocking peripheral afferent input could abolish pain in patients with definite CPSP. Ultrasound-guided lidocaine nerve blocks in the painful extremity produced complete pain abolition in 7 of 8 patients, with the remaining patient achieving more than 50% relief. Mechanical and thermal hypersensitivity were also abolished, and lidocaine blood levels were too low to explain a systemic effect.

A later retrospective series by Choi et al. evaluated ultrasound-guided single-injection peripheral nerve blocks targeted to the primary pain site. Mean immediate pain reduction was 3.3 NRS points, 68% of patients had pain reduction lasting more than one month, and 59% achieved at least 50% pain reduction. No adverse events were reported in that series.

Stellate Ganglion Block

Stellate ganglion block may be considered in selected patients with refractory upper-limb, hemibody or thalamic-type CPSP, particularly where autonomic dysregulation, cold sensitivity, sympathetically maintained pain or vascular temperature change appear clinically relevant. Your article notes Liu 2020 reporting prolonged benefit and Shi 2023 providing preclinical evidence for anti-inflammatory mechanisms.

The evidence remains limited, and stellate ganglion block should not be presented as a universal CPSP treatment. Its role is best framed as a specialist option for carefully selected patients, particularly when the clinical picture suggests a sympathetic or neuroimmune contribution.

Pulsed Radiofrequency

Pulsed radiofrequency delivers short bursts of radiofrequency energy without producing the destructive thermal lesion used in conventional radiofrequency ablation. It is intended to modulate abnormal nerve signalling rather than destroy the nerve. In CPSP, pulsed radiofrequency is theoretically relevant when peripheral afferent drive appears to maintain central sensitisation.

Your article is clear that direct CPSP-specific evidence for pulsed radiofrequency is limited. Evidence is stronger for related post-stroke pain states such as hemiplegic shoulder pain, but its use in true CPSP remains experimental or highly selected. It may be considered after a positive diagnostic peripheral nerve block where the treated nerve or plexus appears to be a meaningful afferent contributor.

Botulinum Toxin Type A for CPSP

Botulinum toxin type A for true CPSP remains off-label and investigational, but your article describes a strong mechanistic rationale. Its analgesic effects are separate from its muscle-relaxing action and may include inhibition of glutamate, CGRP and substance P release from sensory terminals, retrograde axonal transport to sensory ganglia and central terminals, reduced neurotransmitter release, reduced glutamate receptor phosphorylation, attenuation of microglial activation and possible cortical reorganisation.

The best-validated subcutaneous technique comes from the BOTNEP protocol for peripheral neuropathic pain. This does not prove efficacy in CPSP, but it provides a practical and evidence-informed injection framework for selected patients with localised allodynic CPSP.

Treating Widespread Limb Pain with Botox

For widespread CPSP involving a whole limb, botulinum toxin has practical limitations. Your article explains that an entire upper limb may require 80–120 injection sites and an entire lower limb may require 100–150 sites. At 5 units per site, this would exceed the usual 300-unit practical ceiling and may approach doses associated with increased adverse events.

Therefore, the most realistic approach is not to inject the entire limb. Instead, treatment should target the most painful or allodynic subregion within safe dosing limits. This may still produce benefit beyond the injected area through retrograde transport and central neuromodulatory effects, but this should be explained as a selected, adjunctive strategy rather than a guaranteed whole-limb treatment.

BoNT-A for Coexisting Post-Stroke Spasticity

Botulinum toxin has a much clearer established role in post-stroke spasticity. Your article notes that early BoNT-A for post-stroke spasticity may reduce later upper-limb pain and analgesic use, although this relates mainly to spasticity-related nociceptive pain rather than true CPSP. This distinction is important because many patients may have both central neuropathic pain and spasticity-related pain at the same time.

Practical Patient Selection

Comparative Table of Treatment Options for Central Post-Stroke Pain

Central post-stroke pain usually requires a personalised, multimodal treatment plan. The table below summarises the main treatment options discussed in this article, including their likely mechanism, evidence strength, expected benefit, advantages and limitations. It is intended as a practical reference rather than a rigid treatment order.

Stepwise Treatment Algorithm for Central Post-Stroke Pain

There is no single universally accepted treatment algorithm for central post-stroke pain. Management should be individualised, multimodal and phase-based. The practical pathway below is adapted from the treatment framework in this article and should be used as a guide rather than a rigid protocol.

Prognosis and Long-Term Outcomes

Central post-stroke pain is often a long-term condition, but the outlook varies considerably from one person to another. Some patients experience substantial improvement with treatment, while others continue to have persistent symptoms that require ongoing management. The most important message is that meaningful progress is still possible even when the pain does not disappear completely.

In clinical practice, the goal is usually to reduce pain intensity, improve sleep, restore function, support rehabilitation and enhance overall quality of life. A realistic and successful outcome may mean returning to important activities and regaining independence rather than achieving total pain elimination.

What Patients Can Realistically Expect

Factors Associated with Better Outcomes

• Early recognition and prompt treatment.
• Good adherence to medication and rehabilitation programmes.
• Optimisation of sleep, mood and stress management.
• Maintenance of physical activity and functional goals.
• Access to specialist treatments such as rTMS, peripheral nerve blocks or neuromodulation when appropriate.
• Strong multidisciplinary support and realistic treatment expectations.

Factors Associated with More Persistent Pain

• Severe allodynia, painful cold and marked sensory abnormalities.
• Significant sleep disturbance, depression or anxiety.
• Delayed diagnosis and prolonged untreated pain.
• Functional deconditioning and fear-avoidance behaviour.
• Failure to respond to multiple first-line therapies.

Long-Term Management

CPSP often requires ongoing adjustment of treatment over time. Medications may need to be changed, interventional procedures repeated, and rehabilitation goals updated as recovery progresses. Long-term follow-up is particularly important in patients with severe or refractory pain.

The most successful long-term outcomes are usually achieved when treatment combines accurate diagnosis, mechanism-based medication, rehabilitation, psychological support, sleep optimisation and access to specialist interventions when necessary.

Pain Spa Expert Perspective and Treatments Offered

Dr M. Krishna — Consultant in Pain Medicine and Specialist in Advanced Interventional Management of Complex Neuropathic Pain

Central post-stroke pain is one of the most challenging neuropathic pain conditions to diagnose and treat. It often requires detailed sensory assessment, careful review of brain imaging, optimisation of medication, and access to advanced interventional and neuromodulation pathways.

Dr Krishna has extensive experience in the management of complex neuropathic pain syndromes, including central post-stroke pain, thalamic pain, spinal cord injury pain, complex regional pain syndrome, post-herpetic neuralgia and refractory peripheral neuropathic pain. His approach combines modern pain neuroscience with highly precise ultrasound-guided and fluoroscopy-guided procedures.

At Pain Spa, treatment is tailored to the underlying pain mechanisms affecting each individual. Particular attention is given to identifying whether symptoms are driven predominantly by thalamocortical disinhibition, central sensitisation, neuroinflammation, impaired descending inhibition, or persistent peripheral afferent input. This mechanism-based approach helps guide treatment selection and improves the likelihood of meaningful benefit.

For selected patients, Dr Krishna offers advanced procedures such as ultrasound-guided peripheral nerve blocks, pulsed radiofrequency, stellate ganglion block and botulinum toxin injections. When neuromodulation techniques such as rTMS, spinal cord stimulation, motor cortex stimulation or deep brain stimulation may be appropriate, patients can be referred to specialist centres with expertise in these therapies.

Frequently Asked Questions About Central Post-Stroke Pain

Key Clinical Take-Home Messages

References

Key journal articles, guidelines and review papers supporting the diagnosis and management of central post-stroke pain.